Xenetic Biosciences, Inc.: Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Xenetic Biosciences (XBIO) and PeriNess announced the first patient has been dosed in a clinical study evaluating Xenetic's systemic DNase technology in combination with CAR T-cell therapy for large B-cell lymphoma. The study, conducted at Tel Aviv Sourasky University Medical Center, aims to improve CAR T-cell expansion and clinical response. Initial efficacy data is expected in Q2 2027.
How this was made
The 30-second read
Why it matters
The announcement provides fresh primary data on a novel therapeutic approach, potentially influencing investor perception of Xenetic and similar biotech firms.
Market read
First‑in‑human dosing could drive short‑term stock movement and longer‑term valuation based on trial outcomes.
What to watch
Competitive landscape of CAR‑T adjuncts and regulatory timelines could limit upside.
Background
Xenetic Biosciences announced the first patient dosing in a study evaluating its systemic DNase technology with anti‑CD19 CAR‑T cells for large B‑cell lymphoma at Tel Aviv Sourasky University Medical Center.
Ticker impact
First patient dosed in Xenetic's investigator-initiated study of systemic DNase combined with CAR T therapy for large B‑cell lymphoma.
likely modest upside as investors price in clinical progress
New clinical start is a material catalyst for a biotech microcap, though uncertainty remains until data readout.
Market effects
Highlights potential of DNase adjuncts in immuno‑oncology, may spur R&D in similar approaches.
Positive signal for US biotech sector and related CAR‑T developers.
Adds to global interest in novel CAR‑T combination therapies.
Counterpoint
Early‑stage trial may not translate to efficacy; risk of failure could outweigh hype.
Key entities
- companyXenetic Biosciences, Inc.
US‑listed biotech developing systemic DNase technology.
- partnerPeriNess Ltd.
Collaboration partner providing DNase technology.
